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A B S T R A C T
Background: Even if neurocognition is known to affect functional outcomes in schizophrenia, no previous
study has explored the impact of cognition on functionality in delusional disorder (DD). We aimed to
assess the effect of clinical characteristics, symptom dimensions and neuropsychological performance on
psychosocial functioning and self-perceived functional impairment in DD.
Methods: Seventy-five patients with a SCID-I confirmed diagnosis of DD underwent neurocognitive
testing using a neuropsychological battery examining verbal memory, attention, working memory and
executive functions. We assessed psychotic symptoms with the Positive and Negative Syndrome Scale,
and calculated factor scores for four clinical dimensions: Paranoid,Cognitive, Affective and Schizoid. We
conducted hierarchical linear regression models to identify predictors of psychosocial functioning, as
measured with the Global Assessment of Functioning scale, and self-perceived functional impairment, as
measured with the Sheehan’s Disability Inventory.
Results: In the final linear regression models, higher scores in the Paranoid (β = 0.471, p < .001, r2 = 0.273)
and Cognitive (β = 0.325, p < .001, r2 = 0.180) symptomatic dimensions and lower scores in verbal memory
(β = 0.273, p < .05, r2 = 0.075) were significantly associated with poorer psychosocial functioning in
patients with DD. Lower scores in verbal memory (β = 0.337, p < .01, r2 = 0.158) and executive functions
(β = 0.323, p < .01, r2 = 0.094) were significantly associated with higher self-perceived disability.
Conclusions: Impaired verbal memory and cognitive symptoms seem to affect functionality in DD, above
and beyond the severity of the paranoid idea. This suggests a potential role for cognitive interventions in
the management of DD.
© 2018 Elsevier Masson SAS. All rights reserved.
Contents lists available at ScienceDirect
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With an estimated prevalence of 0.03% in clinical samples,
delusional disorder (DD) has been traditionally considered a rare
psychiatric condition [1]. Despite more recent reports of prevalence
rates as high as 0.18% in general population samples [2], empirical
research on DD is sparse relative to other psychotic disorders. Current
diagnostic criteria for delusional disorder [3] are still grounded on
Kraepelin’s concept of paranoia, defined as a chronic, systematized
delusional conditionwith no cognitive deterioration orhallucinations,
unlike schizophrenia (dementia praecox) [4]. Findings regarding* Corresponding author.
E-mail address: covadonga.martinez@iisgm.com (C.M. Díaz-Caneja).
http://dx.doi.org/10.1016/j.eurpsy.2018.09.010
0924-9338/© 2018 Elsevier Masson SAS. All rights reserved.neurocognition in patients with DD have been controversial so far,
with some studies reporting poorer attention and verbal learning
and memory [5–7], executive functioning and working memory [6]
or visuo-spatial ability [8,9] in patients with DD as compared with
healthy controls, and others not finding any significant differences
in neuropsychological performance [10,11]. Most of these studies
are limited by their sample size, which might preclude detecting
significant differences. Still, some evidence suggests the presence of
cognitive deficits in DD similar to those found in schizophrenia, but
possibly subtler [7,8,12]. This is consistent with a recent study
comparing psychopathological dimensions in patients with schizo-
phrenia, schizoaffective disorder and DD. Scores in the cognitive
dimension in DD suggested some degree of cognitive impairment,
though significantly lower than that found in both schizophrenia
and schizoaffective disorder [13].
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its ramifications, functioning is not markedly impaired in
delusional disorder (DD) [3]. To our knowledge, no previous
studies have empirically validated this criterion and explored
whether cognitive deficits and symptom dimensions might have
an impact on functionality in DD above and beyond the impact of
the paranoid idea and its clinical correlates. Considering that
neurocognition is one of the most replicated predictors of
functional outcomes in schizophrenia [14], we sought to test the
hypothesis that neuropsychological performance and cognitive
symptoms will be associated with psychosocial functioning and
self-perceived functional impairment or disability in DD. In
keeping with evidence for a mediation effect of clinical symptoms
between neuropsychological performance and functionality in
schizophrenia [15], we additionally aimed to explore whether the
effect of neuropsychological performance on functionality might
be mediated by clinical dimensions in DD. Finally, considering the
dearth of previous studies assessing correlates of functionality in
DD, we aimed to test whether neurodevelopmental, premorbid
and clinical characteristics of the condition might also impact
functioning and self-perceived disability in DD.
2. Methods
2.1. Participants
We enrolled eighty-six patients with a diagnosis of DD
confirmed with the Structured Clinical Interview for DSM-IV Axis
I Disorders (SCID-I) [16] from five community mental health
centers run by Sant Joan de Déu-Mental Health Services (SJD-MHS)
in Barcelona, Spain, in a cross-sectional study assessing clinical,
neuropsychological and functional characteristics of DD. The
inclusion criteria were: (a) a primary DSM-IV diagnosis of DD
confirmed with the SCID-I, (b) age 18 years or older, (c) residence in
the catchment area of SJD-MHS and (d) at least one outpatient visit
during the six months preceding the beginning of the study. The
exclusion criteria were: (a) clinical diagnosis of mental retardation,
(b) illiteracy, and (c) poor command of the Spanish language. The
Ethics Committee of SJD-MHS approved the study and all patients
gave written informed consent after full explanation of the study
procedures. For the purposes of this study, we only included
participants with available neurocognitive data (N = 75).
2.2. Clinical and functional assessment
We confirmed DD clinical diagnoses using the psychosis
module of the SCID-I [16]. Using Module B of the same instrument
we assessed the presence and type of delusions and hallucinatory
behavior (i.e. tactile, olfactory, or non-prominent auditory, visualTable 1
Individual PANSS items and neuropsychological tests comprising the symptom dimens
Construct Items/Tests
Symptom dimensions [19]
Paranoid dimension Delusions, excitation, lack of judgme
Cognitive dimension Conceptual disorganization, decrease
Schizoid dimension Emotional withdrawal, passive socia
Affective dimension Feelings of guilt, somatic concern, an
Neurocognitive domains
Attention TMT-A; WAIS-III Direct Digit Span, D
Verbal learning and memory TAVEC: Perseverations, Interference,
Working memory TMT B-A; WAIS-III Inverse Digit Spa
Executive functions WCST-64 Perseveration Errors; TMT 
Interference Index
Abbreviations: TMT: Trail Making Test, TAVEC: “Test de Aprendizaje Verbal España Com
Test. †For the purposes of this study, verbal fluency tasks were considered to be a measure
strategies.or gustatory hallucinations related to the delusional theme, not
fulfilling criterion A for schizophrenia and of less than one week of
duration). We assigned patients to one of seven DD DSM-IV types
(persecutory, jealous, somatic, erotomaniac, grandiose, mixed, and
not otherwise specified). We assessed psychotic and general
psychopathology using the Positive and Negative Syndrome Scale
for Schizophrenia (PANSS) [17,18]. Since previous symptomatic
dimensions obtained by factor analysis of the PANSS have been
based on schizophrenia or mixed samples, we calculated scores for
four symptomatic dimensions resulting from a previous factor
analysis in this DD sample (see Table 1) [19]. We also calculated
mean factor scores based on Lindenmayer’s five-factor solution
previously validated in schizophrenia (Positive, Negative, Cognitive,
Depressive and Excitement) [20].
Global functioning was assessed using the Global Assessment of
Functioning (GAF) scale. The GAF is a clinician-rated scale based on a
continuum between mental health and mental disease assessing
psychological, social and occupational functioning, with scores
ranging from 1 to 100, where higher scores represent higher levels of
functioning [21]. We measured self-perceived functional im-
pairment with the Spanish version of Sheehan’s Disability Inventory
(SDI) [22,23]. The SDI is a self-report instrument that assesses
functional impairment in three inter-related areas: work, social and
family life. A global dimensional measure of self-perceived global
functional impairment or disability can be calculated by summing
the scores obtained in each of these three areas, with global scores
ranging from 0 to 30. The SDI has shown good sensitivity and
specificity in patients with several mental conditions [22,23].
We assessed treatment adherence with the Bäuml Treatment
Adherence Scale [24]. This is a clinician-rated instrument that
scores adherence using a 4-point Likert scale, with scores ranging
from 1 (very good adherence) to 4 (poor adherence) [25]. Adverse
experiences before age 18 were assessed using modified questions
of the Conflict Tactics Scale [26]. We assessed axis-I comorbidity
with the Mini International Neuropsychiatric Interview (MINI) for
DSM-IV [27,28] and premorbid personality disorder with the
Standardized Assessment of Personality [29]. A custom question-
naire was used to collect additional demographic data and clinical
variables such as age at onset, duration of illness, treatment delay
(i.e. time elapsed from the onset of the first psychotic symptom to
the first contact with services), psychotropic treatment, type of
onset, course, premorbid auditory deficit, premorbid substance use
disorders, and developmental delay. Further details on the clinical
assessment are available elsewhere [19].
A master’s-level clinical neuropsychologist trained in neuro-
psychological standardized testing procedures, assessment inter-
view techniques, and in the administration of the diagnostic,
psychopathological, and functioning scales used in this study
evaluated all patients.ions and neurocognitive domains used in the study.
nt, suspiciousness, hostility
d speech fluency, motor retardation, decreased ability for abstract thinking
l withdrawal, unusual thought content
xiety, depression
igit-Symbol Coding subtest; Stroop Color and Word Test, Parts A and B.
 Response Bias, Short Delay Free Recall, Long Delay Free Recall indices
n; Phonemic Verbal Fluency Tasks†
B:A; WAIS-III Similarities and Block Design Subtests; Stroop Color and Word Test,
plutense”, WAIS: Wechsler Adult Intelligence Scale, WCST: Wisconsin Card Sorting
 of working memory [54,55], despite the fact that they also require the ability to shift
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We administered a comprehensive battery of tests assessing
four neuropsychological domains pertinent to functioning in
patients with psychosis: attention, verbal learning and memory,
working memory, and executive functions (see Table 1) [30,31].
Neuropsychological assessment was performed in patients con-
sidered to be clinically stable by their treating clinicians. We
standardized test scores using demographically corrected T scores
based on the test manuals and obtained scores for each domain by
computing the mean of the tests addressing each domain. We
estimated pre-morbid IQ with the Wechsler Adult Intelligence
Scale vocabulary subtest (WAIS-III) [32].
2.4. Statistical analysis
We analyzed the demographic and clinical characteristics of the
sample using descriptive statistics (frequencies or mean and SD, as
appropriate). Pearson correlation coefficients or Student’s t tests
were computed to assess the relationship of clinical factors,
symptomatic dimensions and neuropsychological performance
with psychosocial functioning and self-perceived disability, and
between neuropsychological domains and symptomatic dimen-
sions. False discovery rate (FDR) correction for multiple compar-
isons (100 analyses) was implemented using a Benjamini-
Hochberg method. The percentage of tolerated false positives
was 5% (q < 0.05).
We used two sets of hierarchical linear regression models to
assess the association of demographic, clinical variables, symptom
dimensions (Paranoid, Cognitive, Schizoid, and Affective) and the four
neuropsychological domains (attention, verbal learning and
memory, working memory and executive functions) with psycho-
social functioning and self-perceived disability, respectively. First,
we entereddemographic variables (age, sex, years in education, civil
status and living arrangement). Then we entered clinical variables
showing an association at a p < .200 [33] uncorrected threshold in
the bivariate analyses with each of the main outcome variables.
Since treatment delay and mean daily antipsychotic dose were
highly skewed, we applied a log-transformation. In the third and
fourth stages, we entered scores in the four symptom dimensions
and four neurocognitive domains, respectively. At each step, we
entered those variables found to be significant in the previous
model, and we calculated the change in adjusted r2 from the
previous model. We repeated these analyses using the factor scores
based on a previous five-factor solution in schizophrenia. Addition-
al linear regression analyses were conducted with the three
dimensions of the SDI (work, social and family) as outcome
measures.
We used path analysis in Stata to explore a potential mediation
effect of symptom dimensions on the association between
neuropsychological domains and functioning and disability,
including the neuropsychological and symptom dimension vari-
ables and the covariates found to be significant in the final linear
regression models for each outcome. We used maximum likeli-
hood estimation with bootstrapping (10,000 bootstrap samples) to
estimate the parameters of the model with 95% confidence
intervals (CIs).
Statistical significance was set at a two-tailed p value <0.05. All
analyses were performed using SPSS version 21 and Stata 14.
3. Results
Table 2shows the demographic, clinical and neuropsycho-
logical characteristics of the sample and their bivariate
associations with functioning, as measured with the GAF, and
self-perceived disability, as measured with the SDI. Scores in theParanoid and Cognitive dimensions were significantly associated
with the GAF but not with the SDI. Scores in verbal memory were
significantly correlated with scores in the GAF and the SDI, while
scores in executive function were only significantly correlated
with the SDI. After applying an FDR-adjustment for multiple
comparisons, the correlations of the Paranoid and Cognitive
dimensions, and verbal memory with scores in the GAF, as well
as between scores in the SDI and executive function remained
significant (see Table 2).
The Cognitive dimension was negatively correlated with
attention (r=-0.326, p = .004), verbal memory (r=-0.316, p = .006)
and working memory (r=-0.383, p = .001), that is, higher scores in
the Cognitive dimension, indicative of more severe cognitive
symptoms, were associated with lower performance in these
domains. On the contrary, the Affective dimension was positively
correlated with verbal learning and memory (r = 0.266, p = .022)
and working memory (r = 0.238, p = 0.040). We found no significant
associations between the Paranoid and Schizoid dimensions and
any neuropsychological domains.
In the final hierarchical linear regression model, lower
psychosocial functioning, as measured with the GAF, was
significantly associated with older age, being single, higher scores
in the Paranoid and Cognitive symptom dimensions and poorer
performance in verbal learning and memory (F = 21.26, p < .001,
r2 = 0.581; see Table 3). Verbal learning and memory accounted for
7.5% of the explained variance in the model. Exploratory mediation
analyses showed that the effect of verbal memory on psychosocial
functioning in the final model could be partially mediated by its
effect on the Cognitive symptom dimension (proportion mediated =
27.2%; see Fig. 1).
Higher self-perceived functional impairment, as measured
with the SDI, was significantly associated with younger age, being
male, higher number of adverse experiences during childhood
and adolescence, history of any lifetime inpatient admission,
presence of a psychosocial precipitating factor at illness onset
and lower performance in the verbal learning and memory and
executive function domains (F = 11.25, p < .001, r2 = 0.499;
see Table 4). Verbal learning and memory and executive functions
accounted for 9.9% and 3.1% of the explained variance in the SDI,
respectively. Since we detected no significant effect of symptom
dimensions on the SDI, we did not perform mediation analyses for
this outcome. Linear regression analyses including disability in the
work, family and social areas as outcome measures identified
younger age and poorer verbal memory and learning as common
predictors of self-perceived disability in the three areas (see
Supplementary Tables 1 and 2).
We identified a similar set of predictors of global functioning
and self-perceived disability in the linear regression models using
symptom dimensions based on Lindenmayer’s five-factor solution
of the PANSS, previously validated in schizophrenia (see Supple-
mentary Tables 3 and 4).
4. Discussion
This study aimed to explore the effect of neuropsychological
performance on global functioning and self-perceived disability in
patients with DD. We found that the cognitive symptom domain
and verbal memory performance affect global functioning in
patients with DD above and beyond the severity of the paranoid
idea. Poorer verbal memory, as well as executive functioning, is
also associated with self-perceived functional impairment. This
study questions with empirical findings the widespread assump-
tion that functionality in DD is affected only by the delusion or its
ramifications [3]. Our findings also suggest that, similarly to
patients with schizophrenia [14], cognition might be associated
with functionality in patients with DD.
Table 2
Bivariate associations of demographic and clinical variables, symptom dimensions and neuropsychological performance with psychosocial functioning and self-perceived




Mean (SD) or N (%) p p
Age, years 54.77 (14.17) r=-0.245 .034 r=-0.445 <.001*
Sex, female 49 (65.3%) t=3.299 .002* t=-2.954 .004*
Civil status, single 17 (22.7%) t=-1.492 .140 t = 0.597 .552
Living on their own 15 (20.0%) t=-2.033 .046 t=-0.613 .542
Years in education 6.91 (4.68) r = 0.169 .147 r = 0.256 .026
Premorbid IQa 46.49 (7.74) r = 0.134 .257 r=-0.235 .044
Subtype






Age at onset 40.47 (14.52) r = 0.113 .333 r=-0.256 .026
Duration of illness 14.42 (11.79) r=-0.160 .171 r=-0.213 .066
Treatment delay, years 3.52 (5.87) r=-0.127 .284 r=-0.228 .052
Treatment delay, years (log) 0.45 (0.39) r=-0.262 .025 r=-0.212 .072
Family history of schizophrenia in first-degree relatives 10 (13.3%) t=-2.069 .042 t = 0.410 .683
Precipitating factors, yes 34 (45.3%) t = 0.771 .443 t = 1.885 .063
Type of onset, insidious 55 (73.3%) t = 0.503 .616 t=-0.994 .324
Type of course, continuous 71 (94.7%) t=-3.146 .002* t = 0.793 .430
Adverse experiences in childhood or adolescence, yes 47 (62.7%) t = 1.505 .137 t = 0.427 .671
Number of adverse experiences in childhood and adolescence 1.36 (1.24) r = 0.072 .544 r = 0.216 .065
Neurodevelopmental difficulties, yes 39 (52.0%) t=-1.668 .100 t=-0.173 .863
Enuresis/encopresis 15 (20.0%) t=-2.033 .046 t = 0.686 .495
Learning difficulties 30 (40.0%) t=-1.114 .269 t=-0.589 .558
Language acquisition delay 3 (4.0%) t = 0.117 .907 t=-0.226 .942
Psychomotor delay 1 (1.3%) t = 0.369 .713 t=-0.335 .739
Obstetric complications, yes 12 (16.0%) t=-0.392 .696 t = 1.597 .115
Premorbid PD, yes 45 (60.0%) t=-0.596 .553 t = 1.126 .264
Cluster A 34 (45.3%) t=-1.231 .222 t = 0.251 .803
Cluster B 5 (6.7%) t=-0.642 .523 t = 0.135 .893
Cluster C 18 (24.0%) t = 1.403 .165 t=-0.506 .614
Premorbid SUD, yes 11 (14.7%) t = 0.008 .994 t = 0.707 .482
Premorbid auditory deficit, yes 14 (18.7%) t = 1.161 .249 t=-1.181 .242
Comorbidity Axis I, yes 34 (45.3%) t = 0.245 .807 t = 1.039 .302
Medical comorbidity, yes 33 (44.0%) t = 0.542 .589 t = 0.000 >.999
Lifetime hallucinations, yes 29 (38.7%) t = -1.473 .145 t = 0.751 .455
Lifetime non-prominent auditory hallucinations 7 (9.3%) t=-2.973 .004* t = 0.979 .331
Lifetime non-prominent visual hallucinations 4 (5.3%) t=-1.470 .146 t=-0.021 .983
Lifetime olfactory hallucinations 11 (14.7%) t = 0.302 .763 t = 0.707 .482
Lifetime tactile hallucinations 16 (21.3%) t=-0.383 .703 t = 0.729 .469
Lifetime inpatient admission, yes 36 (48.0%) t=-0.656 .514 t = 2.654 .010
Antipsychotic treatment, yes 67 (89.3%) t=0.423 .673 t=-0.155 .877
Mean daily antipsychotic dose 254.19 (266.31) r=-0.167 .153 r = 0.297 .010
Treatment adherence, high 49 (65.3%) t = 1.573 .120 t=-0.071 .944
Symptom dimensions
Paranoiddimension 0.04 (1.03) r=-0.531 <.001* r = 0.161 .168
Cognitive dimension 0.11 (0.86) r=-0.459 <.001* r = 0.103 .378
Affective dimension 0.05 (1.00) r = 0.098 .404 r = 0.113 .336
Schizoiddimension 0.06 (1.02) r=-0.131 .262 r=-0.059 .615
Cognitive domains
Attention 41.85 (6.78) r = 0.223 .054 r=-0.180 .122
Working memory 41.30 (7.15) r = 0.056 .630 r=-0.162 .165
Verbal memory 44.00 (10.78) r = 0.469 <.001* r=-0.307 .008
Executive functions 49.67 (5.54) r = 0.114 .331 r=-0.339 .003*
GAF 64.07 (11.02) – r=-0.243 .035
SDI 13.33 (7.97) r=-0.243 .035 –
Work 5.19 (3.67) r=-0.118 .315 –
Social 4.20 (3.04) r=-0.315 .006 –
Family 4.03 (3.14) r=-0.196 .092 –
Abbreviations: GAF = Global Assessment of Functioning, IQ = Intelligence quotient, PD = Personality disorder, SDI = Sheehan’s Disability Inventory, SUD = Substance use
disorders.
Significant findings (p < .05) are shown in bold. *Significant findings after false discovery rate adjustment using the Benjamini-Hochberg procedure (q<.05).
a Premorbid IQ shown as T-score.
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dimension, which includes the nuclear symptoms of paranoia
(delusions, suspiciousness, hostility, excitation and lack of insight)
and can be conceptualized as an appropriate proxy of “the
delusional idea and its ramifications” in DD, accounted for thegreatest amount of the explained variance in the GAF. However, we
also found that the Cognitive symptom dimension and verbal
memory were independently associated with functioning, as
measured with the GAF, jointly accounting for variance compara-
ble to that accounted for by the Paranoid dimension. We also found
Table 3
Hierarchical linear regression models assessing the association of demographic and clinical variables, symptom dimensions and neuropsychological performance with
psychosocial functioning in delusional disorder.
Variable Model 1 Model 2 Model 3 Model 4





















Adverse experiences in childhood
Enuresis/encopresis in childhood





Type of course, continuous 12.97
(4.85)
0.266b 0.073
Premorbid cluster C PD
Daily antipsychotic dose (log)
High treatment adherence























r2value 0.178 0.292 0.538 0.581
Dr2 – 0.114 0.246 0.043
F value 9.01 8.64 22.56 21.26
p value <.001 <.001 <.001 <.001
Statistic values are only shown for significant predictors in each model. PD: Personality disorder.
a p < .05.
b p < .01.
c p < .001.
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executive functions on self-perceived disability as measured with
the SDI, with no significant effect of the symptom dimensions on
this outcome. We also found similar results for the Positive and
Cognitive clinical dimensions using a five-factor solution of the
PANSS, which has been previously validated in schizophrenia. The
finding of a significant association between the symptom
dimensions and the GAF is not surprising, considering that the
GAF takes into account clinical symptoms in its rating, an issue that
has led to previous criticism of the scale [34]. Nevertheless, even if
the total amount of variance explained by verbal memory in both
models is relatively small, we found a comparable effect on both
functional outcomes, suggesting that verbal memory might be an
independent contributor to both clinician-rated and self-perceived
functioning in DD, even after accounting for the effects of paranoid
and cognitive symptoms.
Previous studies have found that both verbal memory and
executive functions can be impaired in patients with DD relative
to healthy controls [5–7], suggesting the presence of dysfunction
involving the prefrontal cortex and temporolimbic structures, an
idea compatible with recent neuroimaging findings in DD [35,36].
In keeping with our findings, these neurocognitive domains havealso been found to significantly affect functional outcomes in
schizophrenia [14] and other psychotic disorders, such as bipolar
disorder [37]. Deficits in encoding and retrieval of verbal
information and in cognitive flexibility can be associated with
impairments in social cognition and reduced capability to acquire
social skills and implement social problem-solving strategies,
leading to reduced social competence and functional impairment
[38]. Verbal learning and memory seems to be one of the
neurocognitive domains more amenable to cognitive remediation
approaches, which seem to improve neuropsychological and
global functioning in patients with schizophrenia [39]. Consider-
ing the limited response of DD to current pharmacological
options (only about one third of patients show good responses to
medication) [40] or to psychological strategies targeting the
paranoid idea such as cognitive-behavioral approaches [41],
tailored cognitive remediation or training strategies targeting
verbal memory, and possibly abstraction/flexibility processes
could provide functional benefits in this clinical population. These
strategies could be especially helpful in the subgroup of patients
with DD showing greater cognitive deficits [42]. Alternatively,
compensatory approaches or social skill training reducing the
demands on these cognitive functions might also be useful for
Fig. 1. Path model for the association between verbal memory, cognitive symptoms and global functioning.
For verbal memory, statistically significant direct and indirect effects (mediated by the Cognitivesymptom dimension) on the GAF were found (direct effect (c): β = 0.281, 95% CI
[0.085, 0.478], p = .005; indirect effect (a*b): β = 0.105, 95% CI [0.005, 0.204], p = .039, proportion mediated = 27.2%; total effect: β = 0.386, 95% CI [0.179, 0.594], p < .001).
Confidence intervals for the regression coefficients calculated with bootstrapping. Mediation analyses were adjusted for significant predictors in the final linear regression
model for global functioning: age, civil status and score in the Paranoid symptom dimension.
Abbreviations: GAF: global assessment of functioning.
* p < .05, ** p < .01, *** p < .001.
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schizophrenia [30].
We found that the Cognitive symptom dimension (comprising
the items conceptual disorganization, decreased capacity for
abstract thinking, decreased speech fluency and motor retarda-
tion) was negatively correlated with attention, working memory
and verbal learning and memory, along the lines of previous
findings in schizophrenia [43,44]. Deficits in these domains might
result in alterations in prefrontal-cortex mediated storage and
information processing tasks, leading to cognitive and disorgani-
zation symptoms and functional impairment [44]. Indeed, we
found that the effect of verbal memory on global functioning could
be partially mediated through its effect on cognitive symptoms in
the exploratory mediation analyses. On the contrary, we found no
significant associations between any neuropsychological domains
and the Paranoid dimension, which was also consistent with
previous findings on delusions or on positive symptoms of
schizophrenia [43].
We did find an association between male sex and lower
functionality and higher disability in most models. Although a
previous longitudinal study did not find significant differences in
disability between male and female patients with DD [45], our
finding is consistent with previous evidence in schizophrenia [46].
A possible mechanism underlying the association between female
sex and better psychosocial functioning might be better female
performance in verbal learning and memory, consistent with
previous reports in schizophrenia [47]. In our sample, female
patients with DD showed significantly better scores in verbal
learning and memory than males (mean score: 38.58  10.74 in
males, vs. 46.94  90.70 in females, t=-3.409, p = .001), with no
significant differences in any other cognitive domains. We found an
opposite effect of age on functionality and self-perceived disability.
While older age was associated with impaired psychosocial
functioning, younger patients reported higher self-perceived
disability. This may reflect greater discrepancy between expect-
ations and achievements in younger people, leading to greater self-
perception of functional impairment.Global functioning was also significantly associated with non-
prominent auditory hallucinations in the linear regression models,
as well as with family history of schizophrenia and history of
premorbid neurodevelopmental difficulties in the bivariate
associations. Even if most of these variables were not significant
predictors in the final models, they might delineate a subtype of
DD more closely related to schizophrenia, with greater functional
impairment. Contrary to previous findings in schizophrenia, where
duration of untreated psychosis (DUP) constitutes one of the most
replicated predictors of functional outcomes [48], we did not
detect a significant effect of treatment delay on psychosocial
functioning or self-perceived disability in the final regression
models. The different nature, form of onset and usual course of
both psychotic disorders might underlie these differences.
Alternatively, it has been previously noted that the impact of
DUP on some outcomes might be more marked or only noticeable
in samples with relatively short DUP [49]. The fact that our sample
had relatively long delays before treatment could have precluded
finding a significant association between DUP and functioning in
the regression analyses.
This work has numerous limitations. First, this was a cross-
sectional study and does not allow for inferring causality. Second,
we relied on the GAF as the main measure of functionality. Even if
the limitations of the GAF have been previously acknowledged
[34], it is a well-validated instrument that is still extensively used
in clinical and research settings. We also complemented the GAF
with a self-report measure of functional impairment and found
comparable results for the effect of verbal memory on self-
perceived functional impairment in the social, family and work
areas. Third, we did not include any measures of social cognition or
metacognition, which have been found to affect functionality in
people with schizophrenia and other psychotic disorders [14] and
could mediate the effect of neurocognition on functional outcomes
[38,50]. Since social cognition deficits seem to be present in
patients with delusional disorder [51], future studies should
specifically assess the association of social cognition and meta-
cognition with functionality in this population. Fourth, this was a
Table 4
Hierarchical linear regression models assessing the association of clinical variables, symptom dimensions and neuropsychological performance with self-perceived disability
in delusional disorder.
Variable Model 1 Model 2 Model 3* Model 4
























Number of adverse experiences in
childhood
1.44 (0.61) 0.221a 0.039 1.44 (0.61) 0.221a 0.039 1.79 (0.58) 0.276b 0.041
Obstetric complications
Daily antipsychotic dose (log)
Lifetime inpatient admission 4.30 (1.44) 0.268b 0.090 4.30 (1.44) 0.268b 0.090 3.70 (1.43) 0.231a 0.078























r2value 0.270 0.445 0.445 0.499
Dr2 – 0.221 0.221 0.054
F value 14.66 10.62 10.62 11.25
p value <.001 <.001 <.001 <.001
Statistic values are only shown for significant predictors in each model. IQ: Intelligence Quotient. *Since none of the symptom dimensions was significant, the final model for
Model 3 included the same variables as the final model for Model 2. The final model for Model 4 did not include any symptom dimensions, as they were not significant, and
included two cognitive variables (verbal memory and executive functions).
a p < .05.
b p < .01.
c p < .001.
58 C.M. Díaz-Caneja et al. / European Psychiatry 55 (2019) 52–60clinical sample recruited among outpatients attending mental
health services in a rural area, with low educational attainment
and a mean duration of illness of 14 years, and might thus not be
representative of DD in the community. Fifth, even if this is a
relatively large sample for DD considering the relatively low
prevalence and small numbers of patients seeking treatment,
sample size might have affected our results and did not allow us to
perform specific analysis in subtypes of DD. Sixth, the correlation
coefficients in the mediation analyses are small, which makes it
difficult to draw conclusions. Further studies in larger samples are
warranted to replicate these findings. Finally, we did not include a
control group and cannot rule out that the associations found
between neurocognition and functionality might reflect a general
process not specific to DD. Nonetheless, our findings are consistent
with previous reports in schizophrenia, and there is some evidence
that these associations might be, to some extent, specific to
psychotic disorders [52,53].
The limitations notwithstanding, this study constitutes a first
attempt to assess clinical and cognitive correlates of functionality
in DD by combining both a clinician-rated and a subjective
measure of functionality, as well as a comprehensive battery of
neuropsychological measures. We found that cognitive symptoms
and poorer performance in verbal memory may have an effect on
global functioning in DD above and beyond the impact of thedelusional idea. This suggests a potential role for cognitive
remediation and other cognitive interventions in the management
of patients with DD. Considering the limited efficacy of current
treatment strategies for DD, the identification of neurocognitive
domains more strongly associated with functional impairment
could help guide tailored interventions to improve functional
prognosis in this clinical population.
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